window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Cancer vaccine research secures $2.5M NIH award for nanoparticle treatment

    A $2.5m National Institutes of Health award will support research [...]

    September 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Isomab data support safety of angiogenic approaches in coronary artery disease

    A systematic review of more than two decades of clinical [...]

    September 4, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FDA approves Tivicay PD for children with HIV weighing at least 2kg

    ViiV Healthcare has received US FDA approval for Tivicay PD [...]

    September 4, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study

    Agenus has reported deep tumour responses and no observed colorectal [...]

    August 27, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development

    CEPI funds Minapharm’s Phase 1 Bundibugyo Ebola vaccine programme

    CEPI will provide up to $16.5 million to Minapharm to [...]

    August 27, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Sagimet prepares Phase 3 acne trial for first US patients

    Sagimet Biosciences is preparing to begin screening patients for its [...]

    August 27, 2026
  • Advanced Therapies,Drug Delivery & Formulation,Drug Discovery & Development,Research & Development

    Circio and Full Circles Therapeutics combine technologies for in vivo cell therapy

    Circio and Full Circles Therapeutics are combining circular RNA and [...]

    August 27, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Research & Development

    Piramal Pharma reports 22.6% emissions reduction and zero OAI observations in sustainability report

    Piramal Pharma has reported a 22.6% reduction in Scope 1 [...]

    August 26, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain,Research & Development

    Centrix and University of Sussex launch £375,000 data science project for drug development

    Centrix Pharma Solutions and the University of Sussex are using [...]

    August 26, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Research & Development

    How AI is reshaping clinical trials: Saama on the next phase of regulated AI

    Saama’s Chief Customer Success and Growth Officer Ari Srinivasan speaks [...]

    August 26, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top